Literature DB >> 3059059

Pharmacodynamic and biological effects of anti-estrogens in different models.

J R Pasqualini1, C Sumida, N Giambiagi.   

Abstract

The biological response to anti-estrogens is very variable and depends on the animal species considered, the target organ, the parameter studied, and the experimental conditions. Anti-estrogens can bind specifically, (1) to the estrogen receptor, (2) to the typical anti-estrogen specific binding site, and (3) to low density lipoproteins in the plasma. Using a monoclonal antibody against the estrogen receptor, different immunological characteristics of the anti-estrogen-receptor complex can be observed. This difference could explain some of the different biological effects. Studies using different human mammary cancer cell lines (hormone-dependent) show that anti-estrogens are active in decreasing cell proliferation. Also, anti-estrogens can block proteins specifically produced by these cells. Some of these proteins could act as growth or inhibitory factors. Estrogen sulfates are the main precursors of estradiol in breast tissues and this conversion is significantly decreased by anti-estrogens. It is accepted that the main pathway of action of anti-estrogens is through the estrogen receptor, but recent information suggests the possibility that this is not the only step in the mechanism of action of anti-estrogens.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3059059     DOI: 10.1016/0022-4731(88)90013-1

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  8 in total

1.  Influence of antiestrogens on the migration of breast cancer cells using an in vitro wound model.

Authors:  A C Mathew; T T Rajah; G M Hurt; S M Abbas Abidi; J J Dmytryk; J T Pento
Journal:  Clin Exp Metastasis       Date:  1997-07       Impact factor: 5.150

2.  Comparative effect of embryonic mouse fibroblasts (Balb/c-3T3) on the proliferation of hormone-dependent (T-47D) and hormone-independent (MDA-MB-231) human breast cancer cell lines.

Authors:  G Chetrite; L Delalonde; J R Pasqualini
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

3.  Reduction of equilibrative nitrobenzylthioinosine-sensitive nucleoside transporter in tamoxifen-treated MCF-7 cells: an oestrogen-reversible phenomenon.

Authors:  L B Goh; C W Lee
Journal:  Biochem J       Date:  1997-10-01       Impact factor: 3.857

4.  A protein that interacts with members of the nuclear hormone receptor family: identification and cDNA cloning.

Authors:  M Zeiner; U Gehring
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

5.  Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen.

Authors:  M Berry; D Metzger; P Chambon
Journal:  EMBO J       Date:  1990-09       Impact factor: 11.598

6.  Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer.

Authors:  Line L Haugan Moi; Marianne Hauglid Flågeng; Jennifer Gjerde; Andre Madsen; Therese Halvorsen Røst; Oddrun Anita Gudbrandsen; Ernst A Lien; Gunnar Mellgren
Journal:  BMC Cancer       Date:  2012-06-15       Impact factor: 4.430

7.  Tumorigenic effects of tamoxifen on the female genital tract.

Authors:  Kaei Nasu; Noriyuki Takai; Masakazu Nishida; Hisashi Narahara
Journal:  Clin Med Pathol       Date:  2008-03-01

8.  Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer.

Authors:  Sung-Hsin Kuo; Shi-Yi Yang; San-Lin You; Huang-Chun Lien; Ching-Hung Lin; Po-Han Lin; Chiun-Sheng Huang
Journal:  Oncotarget       Date:  2017-03-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.